MyPEEPS LITE Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MyPEEPS Mobile.
- Who it may be relevant to
- Registry conditions: HIV/AIDS. Basic parameters: 16 years — 29 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=3,200), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary individuals that are assigned male sex at birth, 16-29 years of age to determine the efficacy of the MyPEEPS Mobile intervention on reduced incident HIV infections in comparison to a standard of care condition and to examine the degree to which reduced incident HIV infections occurs in the context of potential multilevel moderators and conceptual mediators. This is key to advancing HIV prevention among HIV-negative US persons at extremely high-risk for HIV seroconversion.
Detailed description
In direct response to RFA-AI-21-018, Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional), we proposed to harness innovative electronic methods to conduct a large, rigorous national study collecting and contextualizing epidemiological HIV incidence data in Young Men who have Sex with Men (YMSM) and testing the efficacy of MyPEEPS Mobile, an evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence. We proposed to establish a large national cohort of 3,200 racially and ethnically diverse YMSM 16-29 years old, the age YMSM are most susceptible to HIV acquisition to identify theoretically-driven correlates of HIV seroconversion among a key population experiencing a disproportionate number of new HIV diagnoses.
Randomized controlled trials (RCTs) are considered the gold standard for estimating treatment efficacy because randomization mitigates risk of bias by balancing measured and unmeasured confounders across treatment groups. However, RCTs are costly, time-consuming, and can be challenging to conduct in certain context. We are therefore integrating the robust epidemiological data that we collected during the UG3 phase into the clinical trial design. That integration is a potentially appealing way to generate an external comparator cohort to increase the power of our RCT to estimate the effect of MyPEEPS Mobile on HIV incidence.
Interventions
- Behavioral MyPEEPS Mobile
An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
Primary outcome measures
- HIV Incidence [Time frame: Baseline, 6 month follow up, 12 month follow up.]
- Total Condomless Anal Sex Occurring in the Context of Insufficient PrEP Protection [Time frame: Baseline, 6 month follow up, 12 month follow up.]
Secondary outcome measures (1)
- Self-Reported PrEP Initiation [Time frame: Baseline, 6 month follow up, 12 month follow up.]
Eligibility criteria
Inclusion criteria
- Be between 16-29 years of age;
- Sex assigned at birth is male and identify gender as male or non-binary;
- Understand and read English;
- Live within US and its territories;
- Own or have access to a smartphone;
- Self-report anal sex with someone who has a penis in the last 12 months; and
- Be HIV-negative or status unknown
Exclusion criteria
- Individuals who identify as transgender
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
United States · 2 centers
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
- Columbia University — New York
Identifiers
NCT: NCT06741631 · AAAV4619 · UH3AI169658